Cytel Introduces its Newest Product


New Data-Driven Patient Enrollment Forecasting Software
Learn More

Cytel announces the release of Enforesys ®, a new tool for data-driven enrollment forecasting. The first software of its kind, Enforesys® draws on Cytel’s expertise in mathematical modeling and computer simulation, to create software designed to help feasibility experts mitigate risk, curtail loss of investment capital and protect potential revenue.

Enforesys® responds to an industry-wide call to lower the rate of missed patient enrollment milestones. Currently, more than 35% of discontinued Phase 3 trials cite poor recruitment as the leading cause of trial termination.

“When Cytel learned of the magnitude of the patient recruitment problem, we felt that we could provide a new solution to a challenge eating away at our industry,” said Cytel Vice President Yannis Jemiai. “Armed with these forecasting techniques, clinical operations managers are positioned to assess whether feasibility projections are realistic.”

See More

ClinicDIA Webinar: Integrating Adaptive Trials and Financial Decision-Making

Cytel CTO, Chairman and Co-Founder Nitin Patel and Pharmagellan’s Frank David reveal how developers are using adaptive designs to also determine development funding strategies.

> Download Slides

cytelNew East® 6.3: Adaptive Dose-Escalation Studies, Accurate Trial Predictions

East® 6.3 addresses key design challenges including modern Bayesian dose-escalation trial methods, plus advanced tools for multiplicity adjustment and predicting a study’s future course.

> Learn More

Raptor Wall StreetCytel Supports Raptor Pharma’s First Approved Product

CMO Patrice Rioux reveals how Cytel’s adaptive trial design and data analytics played a pivotal role in orphan status approval for their rare disease treatment.

> Learn More

Nature ArticleJust Published in Nature Journal

Cyrus Mehta, Cytel president and co-founder, co-authored new paper on emerging Efficacy-to-Effectiveness trials in Nature's Clinical Pharmacology & Therapeutics.

> Learn More

cytelVideo Insights

CMO Dr. Adam Craig on aligning the medical and financial rationales in an adaptive sample size re-estimation oncology trial.

> Learn More

Suvoda PartnerCytel and Suvoda Partnership Announced at DIA

Cytel advanced technology will be available from the Suvoda IRT system providing access to validated prediction, implementation, and trial operations-support tools.

> Read Announcement

Marvin ZelenCytel Remembers Friend and Board Member Marvin Zelen

Cytel mourns the loss of Cytel Board Member Professor Marvin Zelen. Marvin was an esteemed statistician, inspiring mentor and beloved friend.